Bevacizumab, irinotecan, temozolomide, tyrosine kinase inhibition, and MEK inhibition are effective against pleomorphic xanthoastrocytoma regardless of V600E status View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2018-11

AUTHORS

Eric M. Thompson, Daniel Landi, David Ashley, Stephen T. Keir, Darell Bigner

ABSTRACT

INTRODUCTION: Pleomorphic xanthoastrocytoma (PXA) is a rare Grade II and III glioma. Surgical resection is the mainstay of treatment, however, adjuvant therapy is sometimes necessary. Given the rarity of PXA, chemotherapeutic efficacy data is limited. The importance of the BRAF V600E mutation in the context of MAP kinase pathway inhibition is unknown. The purpose of this study was to perform an in vivo screen of a variety to agents to determine efficacy against both V600E mutant and non-mutant PXA. METHODS: The efficacy of bevacizumab, temozolomide, lomustine (CCNU), irinotecan (CPT 11), a tyrosine kinase inhibitor (sorafenib), a selective MEK1/2 inhibitor (cobimetinib), and a BRAF inhibitor (vemurafenib) were assessed in two subcutaneous xenografts: D645 PXA (V600E-mutant) and D2363 PXA (V600E-non-mutant) (n = 5-10 mice). Select agents were also assessed in an intracranial model of D2363 PXA (n = 6-9). Subcutaneous tumor growth and survival were the endpoints. RESULTS: Temozolomide, bevacizumab, CPT 11, and sorafenib significantly inhibited subcutaneous tumor growth in both V600E-mutant and V600E-non-mutant models (P < 0.05). MEK inhibition (cobimetinib) but not BRAF inhibition (vemurafenib) also inhibited tumor growth regardless of V600E mutation (P < 0.05). Temozolomide, CPT 11, and bevacizumab also prolonged survival in a V600E-non-mutant intracranial model (median overall survival (OS) 68.5, 62.5, and 42.5 days, respectively) in contrast to controls (31.5 days, P < 0.001). CONCLUSIONS: These findings suggest that when adjuvant treatment is clinically indicated for PXA, temozolomide, CPT 11, or bevacizumab may be considered. Additionally, a trial of a MEK inhibitor or tyrosine kinase inhibitor could be considered for PXA regardless of V600E mutation status. More... »

PAGES

1-8

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s11060-018-2975-5

DOI

http://dx.doi.org/10.1007/s11060-018-2975-5

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1106156654

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30120661


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Duke University Hospital", 
          "id": "https://www.grid.ac/institutes/grid.189509.c", 
          "name": [
            "Department of Neurosurgery, Duke University, Durham, NC, USA", 
            "Preston Robert Tisch Brain Tumor Center, Duke University, Durham, NC, USA", 
            "Duke University Medical Center, Box 3272, 27710, Durham, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Thompson", 
        "givenName": "Eric M.", 
        "id": "sg:person.01333331005.39", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01333331005.39"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Duke University", 
          "id": "https://www.grid.ac/institutes/grid.26009.3d", 
          "name": [
            "Department of Neurosurgery, Duke University, Durham, NC, USA", 
            "Preston Robert Tisch Brain Tumor Center, Duke University, Durham, NC, USA", 
            "Department of Pediatrics, Duke University, Durham, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Landi", 
        "givenName": "Daniel", 
        "id": "sg:person.014042314014.35", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014042314014.35"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Duke University", 
          "id": "https://www.grid.ac/institutes/grid.26009.3d", 
          "name": [
            "Department of Neurosurgery, Duke University, Durham, NC, USA", 
            "Preston Robert Tisch Brain Tumor Center, Duke University, Durham, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ashley", 
        "givenName": "David", 
        "id": "sg:person.01222136634.47", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01222136634.47"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Duke University", 
          "id": "https://www.grid.ac/institutes/grid.26009.3d", 
          "name": [
            "Department of Neurosurgery, Duke University, Durham, NC, USA", 
            "Preston Robert Tisch Brain Tumor Center, Duke University, Durham, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Keir", 
        "givenName": "Stephen T.", 
        "id": "sg:person.0700176300.45", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0700176300.45"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Duke University", 
          "id": "https://www.grid.ac/institutes/grid.26009.3d", 
          "name": [
            "Department of Neurosurgery, Duke University, Durham, NC, USA", 
            "Preston Robert Tisch Brain Tumor Center, Duke University, Durham, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bigner", 
        "givenName": "Darell", 
        "id": "sg:person.013515206217.45", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013515206217.45"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1158/0008-5472.can-11-2837", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002624813"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/2159-8290.cd-14-0049", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006990102"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s12885-015-1672-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007432906", 
          "https://doi.org/10.1186/s12885-015-1672-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1535-7163.mct-08-0138", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008537421"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/neuonc/nos264", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011519237"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/0471141755.ph1416s52", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017267501"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1227/neu.0b013e3182262c5b", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019536867"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11060-012-0991-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020624114", 
          "https://doi.org/10.1007/s11060-012-0991-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00401-011-0802-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021699084", 
          "https://doi.org/10.1007/s00401-011-0802-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3109/02688697.2013.776666", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024472305"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/pbc.25272", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024656901"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1227/01.neu.0000370918.51053.bc", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025819952"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ejso.2015.09.012", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026904455"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/bpa.12217", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027528349"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/neuonc/nou059", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035548400"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11060-013-1176-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042549742", 
          "https://doi.org/10.1007/s11060-013-1176-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1073/pnas.1219232110", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043268845"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/pbc.22490", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046150752"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/pbc.22490", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046150752"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/0008-5472.can-06-1377", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048394980"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11060-016-2195-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048547416", 
          "https://doi.org/10.1007/s11060-016-2195-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11060-016-2195-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048547416", 
          "https://doi.org/10.1007/s11060-016-2195-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1582-4934.2009.00692.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050223514"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1371/journal.pone.0017948", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051579039"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11060-011-0605-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051886763", 
          "https://doi.org/10.1007/s11060-011-0605-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11060-012-0939-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052386465", 
          "https://doi.org/10.1007/s11060-012-0939-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00006123-199911000-00039", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1060250413"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3171/jns.1978.49.4.0579", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1071091614"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3171/jns.1978.49.4.0579", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1071091614"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3171/jns.1978.49.4.0579", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1071091614"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1700/1377.15309", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1078831518"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1079719456", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1212/wnl.0000000000003767", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083957714"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1212/wnl.0000000000003767", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083957714"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1212/wnl.0000000000003767", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083957714"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.18632/oncotarget.17667", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1085208469"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.18632/oncotarget.19875", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1090990181"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2217/cns-2017-0006", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1092116337"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/mph.0000000000001032", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1093143581"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/mph.0000000000001032", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1093143581"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/mph.0000000000001032", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1093143581"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/mph.0000000000001032", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1093143581"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.6004/jnccn.2017.7032", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1100177867"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.6004/jnccn.2017.7032", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1100177867"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/030089161309900507", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1100947742"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/030089161309900507", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1100947742"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jnen/nly045", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1104437881"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-11", 
    "datePublishedReg": "2018-11-01", 
    "description": "INTRODUCTION: Pleomorphic xanthoastrocytoma (PXA) is a rare Grade II and III glioma. Surgical resection is the mainstay of treatment, however, adjuvant therapy is sometimes necessary. Given the rarity of PXA, chemotherapeutic efficacy data is limited. The importance of the BRAF V600E mutation in the context of MAP kinase pathway inhibition is unknown. The purpose of this study was to perform an in vivo screen of a variety to agents to determine efficacy against both V600E mutant and non-mutant PXA.\nMETHODS: The efficacy of bevacizumab, temozolomide, lomustine (CCNU), irinotecan (CPT 11), a tyrosine kinase inhibitor (sorafenib), a selective MEK1/2 inhibitor (cobimetinib), and a BRAF inhibitor (vemurafenib) were assessed in two subcutaneous xenografts: D645 PXA (V600E-mutant) and D2363 PXA (V600E-non-mutant) (n\u2009=\u20095-10 mice). Select agents were also assessed in an intracranial model of D2363 PXA (n\u2009=\u20096-9). Subcutaneous tumor growth and survival were the endpoints.\nRESULTS: Temozolomide, bevacizumab, CPT 11, and sorafenib significantly inhibited subcutaneous tumor growth in both V600E-mutant and V600E-non-mutant models (P\u2009<\u20090.05). MEK inhibition (cobimetinib) but not BRAF inhibition (vemurafenib) also inhibited tumor growth regardless of V600E mutation (P\u2009<\u20090.05). Temozolomide, CPT 11, and bevacizumab also prolonged survival in a V600E-non-mutant intracranial model (median overall survival (OS) 68.5, 62.5, and 42.5\u00a0days, respectively) in contrast to controls (31.5\u00a0days, P\u2009<\u20090.001).\nCONCLUSIONS: These findings suggest that when adjuvant treatment is clinically indicated for PXA, temozolomide, CPT 11, or bevacizumab may be considered. Additionally, a trial of a MEK inhibitor or tyrosine kinase inhibitor could be considered for PXA regardless of V600E mutation status.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s11060-018-2975-5", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1094205", 
        "issn": [
          "0167-594X", 
          "1573-7373"
        ], 
        "name": "Journal of Neuro-Oncology", 
        "type": "Periodical"
      }
    ], 
    "name": "Bevacizumab, irinotecan, temozolomide, tyrosine kinase inhibition, and MEK inhibition are effective against pleomorphic xanthoastrocytoma regardless of V600E status", 
    "pagination": "1-8", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "99667f17b9f3dc632c163eaa4db4204e51bf9c537106273f0c50b59ccb26ac33"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30120661"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8309335"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s11060-018-2975-5"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1106156654"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s11060-018-2975-5", 
      "https://app.dimensions.ai/details/publication/pub.1106156654"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T19:16", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8678_00000557.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1007%2Fs11060-018-2975-5"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s11060-018-2975-5'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s11060-018-2975-5'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s11060-018-2975-5'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s11060-018-2975-5'


 

This table displays all metadata directly associated to this object as RDF triples.

212 TRIPLES      21 PREDICATES      63 URIs      19 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s11060-018-2975-5 schema:about anzsrc-for:11
2 anzsrc-for:1112
3 schema:author Nc41591424c924ac29e7cb772f40d9c4e
4 schema:citation sg:pub.10.1007/s00401-011-0802-6
5 sg:pub.10.1007/s11060-011-0605-6
6 sg:pub.10.1007/s11060-012-0939-8
7 sg:pub.10.1007/s11060-012-0991-4
8 sg:pub.10.1007/s11060-013-1176-5
9 sg:pub.10.1007/s11060-016-2195-9
10 sg:pub.10.1186/s12885-015-1672-4
11 https://app.dimensions.ai/details/publication/pub.1079719456
12 https://doi.org/10.1002/0471141755.ph1416s52
13 https://doi.org/10.1002/pbc.22490
14 https://doi.org/10.1002/pbc.25272
15 https://doi.org/10.1016/j.ejso.2015.09.012
16 https://doi.org/10.1073/pnas.1219232110
17 https://doi.org/10.1093/jnen/nly045
18 https://doi.org/10.1093/neuonc/nos264
19 https://doi.org/10.1093/neuonc/nou059
20 https://doi.org/10.1097/00006123-199911000-00039
21 https://doi.org/10.1097/mph.0000000000001032
22 https://doi.org/10.1111/bpa.12217
23 https://doi.org/10.1111/j.1582-4934.2009.00692.x
24 https://doi.org/10.1158/0008-5472.can-06-1377
25 https://doi.org/10.1158/0008-5472.can-11-2837
26 https://doi.org/10.1158/1535-7163.mct-08-0138
27 https://doi.org/10.1158/2159-8290.cd-14-0049
28 https://doi.org/10.1177/030089161309900507
29 https://doi.org/10.1212/wnl.0000000000003767
30 https://doi.org/10.1227/01.neu.0000370918.51053.bc
31 https://doi.org/10.1227/neu.0b013e3182262c5b
32 https://doi.org/10.1371/journal.pone.0017948
33 https://doi.org/10.1700/1377.15309
34 https://doi.org/10.18632/oncotarget.17667
35 https://doi.org/10.18632/oncotarget.19875
36 https://doi.org/10.2217/cns-2017-0006
37 https://doi.org/10.3109/02688697.2013.776666
38 https://doi.org/10.3171/jns.1978.49.4.0579
39 https://doi.org/10.6004/jnccn.2017.7032
40 schema:datePublished 2018-11
41 schema:datePublishedReg 2018-11-01
42 schema:description INTRODUCTION: Pleomorphic xanthoastrocytoma (PXA) is a rare Grade II and III glioma. Surgical resection is the mainstay of treatment, however, adjuvant therapy is sometimes necessary. Given the rarity of PXA, chemotherapeutic efficacy data is limited. The importance of the BRAF V600E mutation in the context of MAP kinase pathway inhibition is unknown. The purpose of this study was to perform an in vivo screen of a variety to agents to determine efficacy against both V600E mutant and non-mutant PXA. METHODS: The efficacy of bevacizumab, temozolomide, lomustine (CCNU), irinotecan (CPT 11), a tyrosine kinase inhibitor (sorafenib), a selective MEK1/2 inhibitor (cobimetinib), and a BRAF inhibitor (vemurafenib) were assessed in two subcutaneous xenografts: D645 PXA (V600E-mutant) and D2363 PXA (V600E-non-mutant) (n = 5-10 mice). Select agents were also assessed in an intracranial model of D2363 PXA (n = 6-9). Subcutaneous tumor growth and survival were the endpoints. RESULTS: Temozolomide, bevacizumab, CPT 11, and sorafenib significantly inhibited subcutaneous tumor growth in both V600E-mutant and V600E-non-mutant models (P < 0.05). MEK inhibition (cobimetinib) but not BRAF inhibition (vemurafenib) also inhibited tumor growth regardless of V600E mutation (P < 0.05). Temozolomide, CPT 11, and bevacizumab also prolonged survival in a V600E-non-mutant intracranial model (median overall survival (OS) 68.5, 62.5, and 42.5 days, respectively) in contrast to controls (31.5 days, P < 0.001). CONCLUSIONS: These findings suggest that when adjuvant treatment is clinically indicated for PXA, temozolomide, CPT 11, or bevacizumab may be considered. Additionally, a trial of a MEK inhibitor or tyrosine kinase inhibitor could be considered for PXA regardless of V600E mutation status.
43 schema:genre research_article
44 schema:inLanguage en
45 schema:isAccessibleForFree false
46 schema:isPartOf sg:journal.1094205
47 schema:name Bevacizumab, irinotecan, temozolomide, tyrosine kinase inhibition, and MEK inhibition are effective against pleomorphic xanthoastrocytoma regardless of V600E status
48 schema:pagination 1-8
49 schema:productId N21e7043ee3ca4544bd8ce95803cd3c23
50 Ncc0066dd09ac44a9bcac40849e2067af
51 Ncc0c7497b7b24d5b9ac10f344ca219e7
52 Nd3a2d6f7864146e4a48190aff40120df
53 Nf291410a2ce4490d8fb89455aed6b09d
54 schema:sameAs https://app.dimensions.ai/details/publication/pub.1106156654
55 https://doi.org/10.1007/s11060-018-2975-5
56 schema:sdDatePublished 2019-04-10T19:16
57 schema:sdLicense https://scigraph.springernature.com/explorer/license/
58 schema:sdPublisher Na0efde55e3f14d0ba643f3d89340a0b9
59 schema:url https://link.springer.com/10.1007%2Fs11060-018-2975-5
60 sgo:license sg:explorer/license/
61 sgo:sdDataset articles
62 rdf:type schema:ScholarlyArticle
63 N0d761471500440c1b5201c8f06fff351 rdf:first sg:person.01222136634.47
64 rdf:rest Ne8d0613b26264b15bec9068b8ad5aa9d
65 N21e7043ee3ca4544bd8ce95803cd3c23 schema:name dimensions_id
66 schema:value pub.1106156654
67 rdf:type schema:PropertyValue
68 N490759e0580b46a588d9c5b9c6b0fdda rdf:first sg:person.014042314014.35
69 rdf:rest N0d761471500440c1b5201c8f06fff351
70 Na0efde55e3f14d0ba643f3d89340a0b9 schema:name Springer Nature - SN SciGraph project
71 rdf:type schema:Organization
72 Nc41591424c924ac29e7cb772f40d9c4e rdf:first sg:person.01333331005.39
73 rdf:rest N490759e0580b46a588d9c5b9c6b0fdda
74 Ncc0066dd09ac44a9bcac40849e2067af schema:name doi
75 schema:value 10.1007/s11060-018-2975-5
76 rdf:type schema:PropertyValue
77 Ncc0c7497b7b24d5b9ac10f344ca219e7 schema:name nlm_unique_id
78 schema:value 8309335
79 rdf:type schema:PropertyValue
80 Nd3a2d6f7864146e4a48190aff40120df schema:name pubmed_id
81 schema:value 30120661
82 rdf:type schema:PropertyValue
83 Ne434e54f1a0445b3816e930d4e3089a3 rdf:first sg:person.013515206217.45
84 rdf:rest rdf:nil
85 Ne8d0613b26264b15bec9068b8ad5aa9d rdf:first sg:person.0700176300.45
86 rdf:rest Ne434e54f1a0445b3816e930d4e3089a3
87 Nf291410a2ce4490d8fb89455aed6b09d schema:name readcube_id
88 schema:value 99667f17b9f3dc632c163eaa4db4204e51bf9c537106273f0c50b59ccb26ac33
89 rdf:type schema:PropertyValue
90 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
91 schema:name Medical and Health Sciences
92 rdf:type schema:DefinedTerm
93 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
94 schema:name Oncology and Carcinogenesis
95 rdf:type schema:DefinedTerm
96 sg:journal.1094205 schema:issn 0167-594X
97 1573-7373
98 schema:name Journal of Neuro-Oncology
99 rdf:type schema:Periodical
100 sg:person.01222136634.47 schema:affiliation https://www.grid.ac/institutes/grid.26009.3d
101 schema:familyName Ashley
102 schema:givenName David
103 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01222136634.47
104 rdf:type schema:Person
105 sg:person.01333331005.39 schema:affiliation https://www.grid.ac/institutes/grid.189509.c
106 schema:familyName Thompson
107 schema:givenName Eric M.
108 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01333331005.39
109 rdf:type schema:Person
110 sg:person.013515206217.45 schema:affiliation https://www.grid.ac/institutes/grid.26009.3d
111 schema:familyName Bigner
112 schema:givenName Darell
113 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013515206217.45
114 rdf:type schema:Person
115 sg:person.014042314014.35 schema:affiliation https://www.grid.ac/institutes/grid.26009.3d
116 schema:familyName Landi
117 schema:givenName Daniel
118 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014042314014.35
119 rdf:type schema:Person
120 sg:person.0700176300.45 schema:affiliation https://www.grid.ac/institutes/grid.26009.3d
121 schema:familyName Keir
122 schema:givenName Stephen T.
123 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0700176300.45
124 rdf:type schema:Person
125 sg:pub.10.1007/s00401-011-0802-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021699084
126 https://doi.org/10.1007/s00401-011-0802-6
127 rdf:type schema:CreativeWork
128 sg:pub.10.1007/s11060-011-0605-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051886763
129 https://doi.org/10.1007/s11060-011-0605-6
130 rdf:type schema:CreativeWork
131 sg:pub.10.1007/s11060-012-0939-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052386465
132 https://doi.org/10.1007/s11060-012-0939-8
133 rdf:type schema:CreativeWork
134 sg:pub.10.1007/s11060-012-0991-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020624114
135 https://doi.org/10.1007/s11060-012-0991-4
136 rdf:type schema:CreativeWork
137 sg:pub.10.1007/s11060-013-1176-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042549742
138 https://doi.org/10.1007/s11060-013-1176-5
139 rdf:type schema:CreativeWork
140 sg:pub.10.1007/s11060-016-2195-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048547416
141 https://doi.org/10.1007/s11060-016-2195-9
142 rdf:type schema:CreativeWork
143 sg:pub.10.1186/s12885-015-1672-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007432906
144 https://doi.org/10.1186/s12885-015-1672-4
145 rdf:type schema:CreativeWork
146 https://app.dimensions.ai/details/publication/pub.1079719456 schema:CreativeWork
147 https://doi.org/10.1002/0471141755.ph1416s52 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017267501
148 rdf:type schema:CreativeWork
149 https://doi.org/10.1002/pbc.22490 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046150752
150 rdf:type schema:CreativeWork
151 https://doi.org/10.1002/pbc.25272 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024656901
152 rdf:type schema:CreativeWork
153 https://doi.org/10.1016/j.ejso.2015.09.012 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026904455
154 rdf:type schema:CreativeWork
155 https://doi.org/10.1073/pnas.1219232110 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043268845
156 rdf:type schema:CreativeWork
157 https://doi.org/10.1093/jnen/nly045 schema:sameAs https://app.dimensions.ai/details/publication/pub.1104437881
158 rdf:type schema:CreativeWork
159 https://doi.org/10.1093/neuonc/nos264 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011519237
160 rdf:type schema:CreativeWork
161 https://doi.org/10.1093/neuonc/nou059 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035548400
162 rdf:type schema:CreativeWork
163 https://doi.org/10.1097/00006123-199911000-00039 schema:sameAs https://app.dimensions.ai/details/publication/pub.1060250413
164 rdf:type schema:CreativeWork
165 https://doi.org/10.1097/mph.0000000000001032 schema:sameAs https://app.dimensions.ai/details/publication/pub.1093143581
166 rdf:type schema:CreativeWork
167 https://doi.org/10.1111/bpa.12217 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027528349
168 rdf:type schema:CreativeWork
169 https://doi.org/10.1111/j.1582-4934.2009.00692.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1050223514
170 rdf:type schema:CreativeWork
171 https://doi.org/10.1158/0008-5472.can-06-1377 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048394980
172 rdf:type schema:CreativeWork
173 https://doi.org/10.1158/0008-5472.can-11-2837 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002624813
174 rdf:type schema:CreativeWork
175 https://doi.org/10.1158/1535-7163.mct-08-0138 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008537421
176 rdf:type schema:CreativeWork
177 https://doi.org/10.1158/2159-8290.cd-14-0049 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006990102
178 rdf:type schema:CreativeWork
179 https://doi.org/10.1177/030089161309900507 schema:sameAs https://app.dimensions.ai/details/publication/pub.1100947742
180 rdf:type schema:CreativeWork
181 https://doi.org/10.1212/wnl.0000000000003767 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083957714
182 rdf:type schema:CreativeWork
183 https://doi.org/10.1227/01.neu.0000370918.51053.bc schema:sameAs https://app.dimensions.ai/details/publication/pub.1025819952
184 rdf:type schema:CreativeWork
185 https://doi.org/10.1227/neu.0b013e3182262c5b schema:sameAs https://app.dimensions.ai/details/publication/pub.1019536867
186 rdf:type schema:CreativeWork
187 https://doi.org/10.1371/journal.pone.0017948 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051579039
188 rdf:type schema:CreativeWork
189 https://doi.org/10.1700/1377.15309 schema:sameAs https://app.dimensions.ai/details/publication/pub.1078831518
190 rdf:type schema:CreativeWork
191 https://doi.org/10.18632/oncotarget.17667 schema:sameAs https://app.dimensions.ai/details/publication/pub.1085208469
192 rdf:type schema:CreativeWork
193 https://doi.org/10.18632/oncotarget.19875 schema:sameAs https://app.dimensions.ai/details/publication/pub.1090990181
194 rdf:type schema:CreativeWork
195 https://doi.org/10.2217/cns-2017-0006 schema:sameAs https://app.dimensions.ai/details/publication/pub.1092116337
196 rdf:type schema:CreativeWork
197 https://doi.org/10.3109/02688697.2013.776666 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024472305
198 rdf:type schema:CreativeWork
199 https://doi.org/10.3171/jns.1978.49.4.0579 schema:sameAs https://app.dimensions.ai/details/publication/pub.1071091614
200 rdf:type schema:CreativeWork
201 https://doi.org/10.6004/jnccn.2017.7032 schema:sameAs https://app.dimensions.ai/details/publication/pub.1100177867
202 rdf:type schema:CreativeWork
203 https://www.grid.ac/institutes/grid.189509.c schema:alternateName Duke University Hospital
204 schema:name Department of Neurosurgery, Duke University, Durham, NC, USA
205 Duke University Medical Center, Box 3272, 27710, Durham, NC, USA
206 Preston Robert Tisch Brain Tumor Center, Duke University, Durham, NC, USA
207 rdf:type schema:Organization
208 https://www.grid.ac/institutes/grid.26009.3d schema:alternateName Duke University
209 schema:name Department of Neurosurgery, Duke University, Durham, NC, USA
210 Department of Pediatrics, Duke University, Durham, NC, USA
211 Preston Robert Tisch Brain Tumor Center, Duke University, Durham, NC, USA
212 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...